Treatment of blepharitis: Recent clinical trials

Stephen C. Pflugfelder, Paul M. Karpecki, Victor L Perez Quinones

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Blepharitis is a chronic inflammatory disease of the eyelids that is frequently encountered in clinical practice. The etiology of the disorder is complex and not fully understood, but the general consensus is that bacteria and inflammation contribute to the pathology. Blepharitis can be classified into anterior blepharitis, involving the anterior lid margin and eyelashes, and posterior blepharitis, characterized by dysfunction of the meibomian glands. Long-term management of symptoms may include daily eyelid cleansing routines and the use of therapeutic agents that reduce infection and inflammation. A cure is not possible in most cases, and subjective symptoms may persist even when a clinical assessment of signs indicates that the condition has improved. There are no established guidelines regarding therapeutic regimens, but recent clinical trials have shown that antibiotics and topical corticosteroids can produce significant improvement in signs and symptoms of blepharitis. Fixed combinations of a topical antibiotic and a corticosteroid offer an effective and convenient treatment modality that addresses both infectious and inflammatory components of the disease. Further clinical trials are needed to determine optimal therapies for managing blepharitis.

Original languageEnglish
Pages (from-to)273-284
Number of pages12
JournalOcular Surface
Volume12
Issue number4
StatePublished - 2014

Keywords

  • Antibiotics
  • Bacteria
  • Blepharitis
  • Corticosteroids
  • Cyclosporine
  • Inflammation
  • Meibomian gland dysfunction

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Treatment of blepharitis: Recent clinical trials'. Together they form a unique fingerprint.

  • Cite this

    Pflugfelder, S. C., Karpecki, P. M., & Perez Quinones, V. L. (2014). Treatment of blepharitis: Recent clinical trials. Ocular Surface, 12(4), 273-284.